The risk of ovarian cancer algorithm (ROCA), based upon serial measurements of cancer antigen 125 (CA-125), can double the number of screen-detected ovarian cancers, compared with a single measurement of the marker. The test, developed by Abcodia (United Kingdom) is set to be released both in the United States and the United Kingdom later this year. “The test represents a unique opportunity to address a significant clinical unmet need for any post-menopausal woman or pre-menopausal women with a clear family history of ovarian cancer,” said Julie Barnes, Ph.D., cofounder and CEO of Abcodia, in a statement. Recent clinical trial results “highlight the sophistication of ROCA in being able to accurately distinguish between asymptomatic women with and without ovarian cancer, despite in many cases, their serum CA125 level appearing within the normal range.” In mid-May, Abcodia announced raising an $8 million round of venture capital financing, which will allow it to launch the ROCA test in the United Kingdom this summer (following CE Mark) and in U.S. markets later in 2015 as a laboratory-developed test. In the United Kingdom, Abcodia says, the test will cost about $229. The ROCA test, the company says, is more effective than traditional, single measurements of […]